Carolinas HealthCare System

Research and Clinical Trials

Breast - Female 

Brief Description Principal Investigator
To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
White, Richard Laverne 
This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer White, Richard Laverne 
The purpose of this study is to evaluate the objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic tumors. Amin, Asim 
To estimate the efficacy of ipatasertib combined with paclitaxel compared with placebo combined with paclitaxel in patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC), as measured by progression-free survival (PFS) in all patients and in patients with PTEN-low tumors. Tan, Antoinette Roslyn 
The purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex. White, Richard Laverne 
NSABP B-50-I: A randomized, multicenter, open-label phase III study to evaluate the eff Limentani, Steven Amedeo 
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer

Sharp, Hadley Jean 
To compare invasive disease-free survival (DFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer randomized to either chemotherapy plus 1 year of trastuzumab plus pertuzumab or chemotherapy plus 1 year of trastuzumab emtansine plus pertuzumab. Fisher, Julie Gottlieb 
To compare the pathological complete response (pCR) rate between treatment arms using central evaulation. Limentani, Steven Amedeo 
Primary Objective
To determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX┬«. In patients with 1-3 positive nodes, and hormone receptor (HR)-positive, HER2-negative breast cancer with RS ≤ 25 treated with endocrine therapy we will test whether the difference in disease-free survival for patients treated with chemotherapy compared to no chemotherapy depends directly on the magnitude of RS. If benefit dep
Schwartz, Garry Howard 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.